Balerna (Switzerland), October 24th 2013
APR is pleased to announce its contribution as a community sponsor to the organization of the 2013 Pisa International Diabetic Foot Course.
The Pisa International Diabetic Foot Courses are organized in partnership with the specialized Diabetic Foot Clinic at the University Hospital of Pisa with the intent of supporting an international educational network by discussing and implementing solutions to the challenges related to treatment and prevention of diabetic foot ulcers.
APR, which shares the objective of improving the outcomes of patient management in this therapeutic area, has developed a novel and innovative product for the management of a variety of wound conditions such as acute wounds, burns and advanced ulcers including venous and pressure ulcers and diabetic foot ulcers. The product was recently granted the European CE approval under the Nexodyn® brand name.
Nexodyn® has been developed based on APRs proprietary technology TEHCLO®, enabling the production of acidic and super-oxidizing solutions containing free chlorine species, of which stabilized hypochlorous acid in very high concentration (> 95%). Nexodyn®, also characterized by acidic and super-oxidizing features in an easy-to-use formulation, acts by improving the functional conditions of the physiological wound healing process, providing the healthcare professional and the patient with an effective, convenient and patient-friendly treatment option.
“APR is very committed in developing innovative products benefiting the patients and the healthcare community in therapeutic areas with significant unmet medical needs.” said Giorgio Reiner, CSO of APR. “Diabetic foot ulcers represent a serious and potentially highly debilitating condition for diabetic patients, with noteworthy impacts on patients lives and cost of cure. A relatively simple treatment coupled with a careful and timely identification of diabetic foot ulcer signs could help improve the overall management of diabetic foot ulcers with a huge return on patients quality of life. APRs novel product for the management of advanced wounds could bring an easy-to-use and effective tool in the armamentarium of the involved medical professional teams as well as the patient thanks to its features of creating conditions favorable to the normal ulcer closure process.”
About APR Applied Pharma Research s.a.
APR is an independent, international and integrated Healthcare Company headquartered in Switzerland and focused on three major areas: Delivering, Funding and Supporting Innovation in Healthcare. In particular, APR develops and licenses innovative, value added and patented healthcare products and proprietary drug delivery systems primarily in the oral and topical fields; APR also invests in companies or early stage innovative projects and provides a balanced mix of equity funding and/or financing together with APRs development, scientific, technical, marketing, licensing and management skills and know how; finally, APR supports biotech and pharmaceutical companies in the development of new pharmaceutical projects by providing on a contract basis added value, consultancy and R&D services under contract using a General Contractor approach. APR has entered into licensing and partnership agreements with pharmaceutical companies in over 100 countries worldwide with international sales on a worldwide basis.